Clinical Trial Update: Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients [Phase 3]

View source ↗

Summary

Phase 3 study to assess the pharmacokinetics, safety, and tolerability of iptacopan in pediatric patients with paroxysmal nocturnal hemoglobinuria. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Status: RECRUITING